DRREDDY2026-09-21DRREDDY2026-09-21in-capmkt:ArrangementsForStrategicOrTechnicalOrManufacturingOrMarketingTieUpMemberDRREDDYDR. REDDY'S LABORATORIES LIMITED500124NOTLISTEDINE089A01031Arrangement/Adoption of new line/Closure of operations (Sub-para 2-Para B)Arrangements for strategic, technical, manufacturing, or marketing tie upNewfalse2026-09-1808:50:002026-09-21AgreementTakeda Biopharmaceuticals India Private LimitedExclusive distribution and marketing of Qdenga® in the private market in IndiaDomesticNot ApplicablePursuant to terms of the Agreement, Dr. Reddy’s will be exclusively responsible for distribution and marketing of Qdenga® in the private market in India, while Takeda will retain commercialization rights in the public market in India, and will be responsible for manufacturing and importation of the vaccine.There is no upfront consideration or milestone payment under the agreement. Other commercial terms are confidential in nature.Pursuant to the terms of the Agreement, Dr. Reddy’s has exclusive distribution and marketing rights for Qdenga® in the private market in India.falseNot ApplicableThe partnership is aligned with Dr. Reddy's strategy to strengthen its vaccines business in India and supports broader public health efforts aimed at addressing the significant burden of dengue in India.